↓ Skip to main content

Hematological approaches to multiple myeloma: trends from a Brazilian subset of hematologists. A cross-sectional study

Overview of attention for article published in Sao Paulo Medical Journal, August 2016
Altmetric Badge

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
31 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Hematological approaches to multiple myeloma: trends from a Brazilian subset of hematologists. A cross-sectional study
Published in
Sao Paulo Medical Journal, August 2016
DOI 10.1590/1516-3180.2015.0223030416
Pubmed ID
Authors

Lucila Nassif Kerbauy, Simrit Parmar, José Mauro Kutner, Breno Moreno de Gusmão, Nelson Hamerschlak

Abstract

For the last nine years, hematologists and oncologists have gathered annually at an educational symposium organized by a Brazilian and an American hospital. During the 2015 Board Review, a survey among the attendees evaluated the differences in management and treatment methods for multiple myeloma (MM). Cross-sectional study during an educational hematology symposium in São Paulo, Brazil. Hematologists present at the symposium gave responses to an electronic survey by means of mobile phone. Among the 350 attendees, 217 answered the questionnaire. Most of the participants believed that immunotargeting agents (iTA) might be effective for slowing MM progression in heavily pretreated patients (67%) and that continued exposure to therapy might lead to emergence of resistant clones in patients with MM (76%). Most of the physicians use maintenance therapy after hematopoietic stem cell transplantation (95%) and 45% of them would further restrict it to post-transplantation patients with underlying high-risk disease. The first-line drugs used for transplantation-ineligible patients (TI-MM) were bortezomib-thalidomide-dexamethasone (31%), bortezomib-dexamethasone (28%), lenalidomide-dexamethasone (Rd; 17%) and melphalan-based therapy (10%). Lenalidomide was the drug of choice for post-transplantation maintenance for half of the participants. No significant differences were observed regarding age or length of experience. The treatment choices for TI-MM patients were highly heterogenous and the melphalan-based regimen represented only 10% of the first-line options. Use of maintenance therapy after transplantation was a common choice. Some results from the survey were divergent from the evidence in the literature.

Mendeley readers

The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 31 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 16%
Student > Ph. D. Student 5 16%
Other 4 13%
Student > Master 3 10%
Professor > Associate Professor 2 6%
Other 6 19%
Unknown 6 19%
Readers by discipline Count As %
Medicine and Dentistry 11 35%
Psychology 3 10%
Social Sciences 2 6%
Agricultural and Biological Sciences 1 3%
Immunology and Microbiology 1 3%
Other 5 16%
Unknown 8 26%